secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001193125-23-241849
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics reports positive Phase 2a INTEGRIS-PSC data for bexotegrast in PSC
--------------------------------------------------------------------------------

- Trial met primary safety endpoint; bexotegrast well tolerated with 94% completing 12 weeks, no drug-related SAEs.
- Exploratory efficacy: significant reduction in ELF score and PRO-C3 at 160 mg vs placebo at Week 12.
- Dose-dependent trend in ALP reduction; MRI imaging suggests improved hepatocyte function and bile flow.
- High-dose 320 mg interim data expected Q1 2024; full 24-week data mid-2024.
- Company to host webcast today at 8:00 AM ET to discuss results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312523241849/0001193125-23-241849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312523241849/d473253d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-241849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer